deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04718103

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype (SWIFT-2)

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Sponsor: GlaxoSmithKline

Conditions Asthma
Interventions GSK3511294 Placebo
Updated 18 times since 2021 Last updated: Nov 22, 2024 Started: Feb 4, 2021 Primary completion: Apr 11, 2024 Completion: Apr 11, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Asthma and is currently completed. GlaxoSmithKline leads this study, which shows 18 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Nov 2022 · 10 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

18 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Dec 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE3

  5. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 13 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  5. Jan 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  6. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  7. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  8. Jan 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  9. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  10. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  11. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  12. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  13. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • Iqvia Pty Ltd
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Alabaster, United States , Allen, United States , Almería, Spain , Altoona, United States , Annecy, France , Atlanta, United States , Aventura, United States , Badalona, Spain , Barcelona, Spain and 98 more locations